This article outlines the development of a world-first pancreatic cancer early detection blood test by BCAL Diagnostics and ClearNote Health. The test identifies cancer-driving proteins, tumour DNA changes, and messenger RNA circulating in the bloodstream before symptoms develop.
The article explains that pancreatic cancer is difficult to diagnose early and often presents with vague symptoms such as abdominal discomfort, digestive changes, or metabolic disturbances. Because most cases are diagnosed late, survival rates are extremely poor unless the disease is caught early enough for surgery.
Researchers say the Avantect Pancreatic Test leverages advances in genomics and epigenetic analysis to identify tumour signatures in blood. Clinical trial data showed strong performance for stage 1 and 2 pancreatic cancer detection, with sensitivity rates of approximately 82.6% and a false-positive rate of 2.5%.
The article notes that the technology is being evaluated in major international studies including the SAFE-D trial and the Vanguard Trial in the US. It is intended initially for high-risk populations including people with BRCA mutations, strong family histories, or chronic pancreatic conditions.
Experts quoted describe the test as a potentially transformative advance that could improve survival outcomes by enabling earlier intervention and treatment.
